Journal article
Antibody responses to the RTS,S/AS01E vaccine and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique
L Sanchez, M Vidal, C Jairoce, R Aguilar, I Ubillos, I Cuamba, AJ Nhabomba, NA Williams, N Díez-Padrisa, D Cavanagh, E Angov, RL Coppel, D Gaur, JG Beeson, S Dutta, P Aide, JJ Campo, G Moncunill, C Dobaño
Npj Vaccines | Published : 2020
Open access
Abstract
The RTS,S/AS01E vaccine has shown consistent but partial vaccine efficacy in a pediatric phase 3 clinical trial using a 3-dose immunization schedule. A fourth-dose 18 months after the primary vaccination was shown to restore the waning efficacy. However, only total IgG against the immunodominant malaria vaccine epitope has been analyzed following the booster. To better characterize the magnitude, nature, and longevity of the immune response to the booster, we measured levels of total IgM, IgG, and IgG1-4 subclasses against three constructs of the circumsporozoite protein (CSP) and the hepatitis B surface antigen (HBsAg, also present in RTS,S) by quantitative suspension array technology in 50..
View full abstractRelated Projects (1)
Grants
Awarded by European Commission
Funding Acknowledgements
We are grateful to the Manhica volunteers and their families; the clinical, field, and lab teams at CISM; the MAL067 Vaccine Immunology Consortium investigators; the hyper-immune plasma suppliers (NIBSC, UK); Hector Sanz for database management and statistical support. We thank the researchers from the labs that produced the recombinant proteins. We thank GlaxoSmithKline Biologicals S.A. for their support in the conduct of the MAL055 study. Work received funding from the NIH-NIAID (R01AI095789), PATH Malaria Vaccine Initiative (MVI), Ministerio de Economia y Competitividad (Instituto de Salud Carlos III, PI11/00423 and PI17/02044) cofounded by FEDER funds/European Regional Development Fund (ERDF), and EVIMalaR and AGAUR-Catalonia (2014 SGR991), and National Health and Medical Research Council of Australia (1077636 and 1092789). L.S., registered in the EMJMD LIVE (Erasmus+ Mundus Joint Master Degree Leading International Vaccinology Education, award 2015-2323), co-funded by the EACEA (Education, Audiovisual and Culture Executive Agency) of the European commission, received a scholarship from the EACEA. G.M. was a recipient of a Sara Borrell-ISCIII fellowship (CD010/00156) and had the support of the Department of Health, Catalan Government (SLT006/17/00109). C.J. was supported by an AGAUR-FI scholarship (2019 FI_B 00986) granted by the Secretaria d'Universitats i Recerca del Departament d'Empresa i Coneixement de la Generalitat de Catalunya and co-funded with Social European Fund. ISGlobal is a member of the CERCA Program, Generalitat de Catalunya.